Oceanapiside, a Marine Natural Product, Targets the Sphingolipid Pathway of Fluconazole-Resistant

Overview

Journal Mar Drugs

Publisher MDPI

Specialties Biology
Pharmacology

Date 2021 Mar 3

PMID 33652774

Citations 6

Authors

Doralyn S Dalisay

Evan W Rogers

Tadeusz F Molinski

Affiliations

Soon will be listed here.

Abstract

Oceanapiside (OPS), a marine natural product with a novel bifunctional sphingolipid structure, is fungicidal against fluconazole-resistant at 10 μg/mL (15.4 μM). The fungicidal effect was observed at 3 to 4 h after exposure to cells. Cytological and morphological studies revealed that OPS affects the budding patterns of treated yeast cells with a significant increase in the number of cells with single small buds. In addition, this budding morphology was found to be sensitive in the presence of OPS. Moreover, the number of cells with single medium-sized buds and cells with single large buds were decreased significantly, indicating that fewer cells were transformed to these budding patterns, suggestive of inhibition of polarized growth. OPS was also observed to disrupt the organized actin assembly in , which correlates with inhibition of budding and polarized growth. It was also demonstrated that phytosphingosine (PHS) reversed the antifungal activity of oceanapiside. We quantified the amount of long chain-bases (LCBs) and phytoceramide from the crude extracts of treated cells using LC-ESI-MS. PHS concentration was elevated in extracts of cells treated with OPS when compared with cells treated with miconazole and amphotericin B. Elevated levels of PHS in OPS-treated cells confirms that OPS affects the pathway at a step downstream of PHS synthesis. These results also demonstrated that OPS has a mechanism of action different to those of miconazole and amphotericin B and interdicts fungal sphingolipid metabolism by specifically inhibiting the step converting PHS to phytoceramide.

Citing Articles

Structure Diversity and Properties of Some Bola-like Natural Products.

Stonik V, Makarieva T, Shubina L, Guzii A, Ivanchina N Mar Drugs. 2025; 23(1).

PMID: 39852505 PMC: 11767167. DOI: 10.3390/md23010003.

Marine Pharmacology in 2019-2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous....

Mayer A, Mayer V, Swanson-Mungerson M, Pierce M, Rodriguez A, Nakamura F Mar Drugs. 2024; 22(7).

PMID: 39057418 PMC: 11278370. DOI: 10.3390/md22070309.

Marine-Derived Metabolites Act as Promising Antifungal Agents.

Hang S, Lu H, Jiang Y Mar Drugs. 2024; 22(4).

PMID: 38667797 PMC: 11051449. DOI: 10.3390/md22040180.

Anti-Candidal Marine Natural Products: A Review.

Ganeshkumar A, Goncale J, Rajaram R, Junqueira J J Fungi (Basel). 2023; 9(8).

PMID: 37623571 PMC: 10455659. DOI: 10.3390/jof9080800.

Marine Compounds with Anti- sp. Activity: A Promised "Land" for New Antifungals.

Alves A, Cruz-Martins N, Rodrigues C J Fungi (Basel). 2022; 8(7).

PMID: 35887426 PMC: 9320905. DOI: 10.3390/jof8070669.

References

Gale A, Sakhawala R, Levitan A, Sharan R, Berman J, Timp W . Identification of Essential Genes and Fluconazole Susceptibility Genes in by Profiling Transposon Insertions. G3 (Bethesda). 2020; 10(10):3859-3870. PMC: 7534453. DOI: 10.1534/g3.120.401595. View

Lester R, Dickson R . High-performance liquid chromatography analysis of molecular species of sphingolipid-related long chain bases and long chain base phosphates in Saccharomyces cerevisiae after derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate. Anal Biochem. 2001; 298(2):283-92. DOI: 10.1006/abio.2001.5368. View

Dickson R, Lester R . Sphingolipid functions in Saccharomyces cerevisiae. Biochim Biophys Acta. 2002; 1583(1):13-25. DOI: 10.1016/s1388-1981(02)00210-x. View

Friant S, Lombardi R, Schmelzle T, Hall M, Riezman H . Sphingoid base signaling via Pkh kinases is required for endocytosis in yeast. EMBO J. 2001; 20(23):6783-92. PMC: 125749. DOI: 10.1093/emboj/20.23.6783. View

Pfaller M, Diekema D . Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1):133-63. PMC: 1797637. DOI: 10.1128/CMR.00029-06. View

Garabedian M, Wirshing A, Vakhrusheva A, Turegun B, Sokolova O, Goode B . A septin-Hof1 scaffold at the yeast bud neck binds and organizes actin cables. Mol Biol Cell. 2020; 31(18):1988-2001. PMC: 7543067. DOI: 10.1091/mbc.E19-12-0693. View

Buede R, Pinto W, Lester R, Dickson R . Cloning and characterization of LCB1, a Saccharomyces gene required for biosynthesis of the long-chain base component of sphingolipids. J Bacteriol. 1991; 173(14):4325-32. PMC: 208092. DOI: 10.1128/jb.173.14.4325-4332.1991. View

Nguyen M, Peacock Jr J, Morris A, Tanner D, Nguyen M, Snydman D . The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996; 100(6):617-23. DOI: 10.1016/s0002-9343(95)00010-0. View

Nicholas G, Li R, MacMillan J, Molinski T . Antifungal activity of bifunctional sphingolipids. Intramolecular synergism within long-chain alpha,omega-bis-aminoalcohols. Bioorg Med Chem Lett. 2002; 12(16):2159-62. DOI: 10.1016/s0960-894x(02)00367-0. View

10.

Mota Fernandes C, Del Poeta M . Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies. Expert Rev Anti Infect Ther. 2020; 18(11):1083-1092. PMC: 7657966. DOI: 10.1080/14787210.2020.1792288. View

11.

Nagiec M, Nagiec E, Baltisberger J, Wells G, Lester R, Dickson R . Sphingolipid synthesis as a target for antifungal drugs. Complementation of the inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces cerevisiae by the AUR1 gene. J Biol Chem. 1997; 272(15):9809-17. DOI: 10.1074/jbc.272.15.9809. View

12.

Nagiec M, Young C, Zaworski P, Kobayashi S . Yeast sphingolipid bypass mutants as indicators of antifungal agents selectively targeting sphingolipid synthesis. Biochem Biophys Res Commun. 2003; 307(2):369-74. DOI: 10.1016/s0006-291x(03)01164-1. View

13.

Kucsera J, Yarita K, Takeo K . Simple detection method for distinguishing dead and living yeast colonies. J Microbiol Methods. 2000; 41(1):19-21. DOI: 10.1016/s0167-7012(00)00136-6. View

14.

Akram Z, Ahmed I, Mack H, Kaur R, Silva R, Castilho B . Yeast as a Model to Understand Actin-Mediated Cellular Functions in Mammals-Illustrated with Four Actin Cytoskeleton Proteins. Cells. 2020; 9(3). PMC: 7140605. DOI: 10.3390/cells9030672. View

15.

Montefusco D, Matmati N, Hannun Y . The yeast sphingolipid signaling landscape. Chem Phys Lipids. 2013; 177:26-40. PMC: 4211598. DOI: 10.1016/j.chemphyslip.2013.10.006. View

16.

Dickson R, Sumanasekera C, Lester R . Functions and metabolism of sphingolipids in Saccharomyces cerevisiae. Prog Lipid Res. 2006; 45(6):447-65. DOI: 10.1016/j.plipres.2006.03.004. View

17.

Vazquez J, Sobel J, Peng G, Steele-Moore L, Schuman P, Holloway W . Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis. 1999; 28(5):1025-31. DOI: 10.1086/514746. View

18.

Millard P, Roth B, Thi H, YUE S, Haugland R . Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts. Appl Environ Microbiol. 1997; 63(7):2897-905. PMC: 168585. DOI: 10.1128/aem.63.7.2897-2905.1997. View

19.

McEvoy K, Normile T, Del Poeta M . Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway. J Fungi (Basel). 2020; 6(3). PMC: 7559796. DOI: 10.3390/jof6030142. View

20.

Vanden Bossche H, Willemsens G, Marichal P . Anti-Candida drugs--the biochemical basis for their activity. Crit Rev Microbiol. 1987; 15(1):57-72. DOI: 10.3109/10408418709104448. View